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INTRODUCTION
In pregnant women with mechanical heart valves, the fre-
quency of valve thrombosis increases due to pregnancy-relat-
ed hypercoagulability. Therefore, effective anticoagulation is
critical in pregnant patients with mechanical heart valves
but remains problematic because both oral anticoagulation
and heparins have been associated with important fetal and
maternal side effects (1).
Coumarin derivatives are anticoagulants of choice for mecha-
nical heart valves, but they cross the placenta and are associ-
ated with coumarin-induced fetal loss or embryopathy (1-3).
Unfractionated heparin (UFH) provides an alternative therapy
that avoids fetal side effects, however, the use of UFH is asso-
ciated with increased maternal thromboembolic and bleeding
complications (1, 4, 5). Low molecular weight heparin (LM-
WH) may be more advantageous than UFH (6), and appears
a good alternative. However, little clinical information and no
reliable data are available regarding its efficacy and safety.
No consensus has been reached about optimal antithrom-
botic therapy in pregnant patients with a mechanical heart
valve. Coumarins are contraindicated in pregnancy in North
America due to fetal concerns, but European experts have
recommended low dose coumarins (less than 5 mg daily)
throughout pregnancy given a very low frequency of fetal
anomalies (2, 3). Reports of LMWH use began to appear, and
many physicians now use LMWH because of its good safety
profile for both mother and baby (7-10). However, treatment
failures have been reported (11, 12), and no LMWH has been
licensed for use in pregnant patients with mechanical heart
valves. Thus, physicians and patients face dilemmas when
making decisions on anticoagulation therapy.
Available published data regarding the efficacy and safety
of LMWH in this clinical setting have been derived from small
case series, and usually enoxaparin has been used. Here, we
report our experience of nadroparin treatment, and its asso-
ciated pregnancy outcomes and maternal complications.
MATERIALS AND METHODS
Between 1997 and 2005, 31 pregnancies were analyzed
retrospectively in 25 women with mechanical heart valves.
Basic characteristics and previous operative data are listed in
Table 1. In 23 of these 31 pregnancies, nadroparin was used as
an anticoagulant during the first trimester with given informed
Jae Hoon Lee, Nam Hee Park, 
Dong Yoon Keum, Sae Young Choi,
Ki Young Kwon*, Chi Heum Cho
�
Department of Thoracic and Cardiovascular Surgery,
Dongsan Medical Center, Keimyung University School
of Medicine; Division of Hematology, Department of
Internal Medicine*, Gynecology and Obstetrics
� ,
Dongsan Medical Center, Keimyung University School
of Medicine, Daegu, Korea
Address for correspondence
Nam Hee Park, M.D.
Department of Thoracic and Cardiovascular Surgery,
Dongsan Medical Center, Keimyung University School
of Medicine, 194 Dongsan-dong, Joong-gu, Daegu
700-712, Korea
Tel : +82.53-250-7025, Fax : +82.53-250-7307
E-mail : nhpark@dsmc.or.kr
258
J Korean Med Sci 2007; 22: 258-61
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Low Molecular Weight Heparin Treatment in Pregnant Women with a
Mechanical Heart Valve Prosthesis
No definitive recommendation is available concerning optimal antithrombotic ther-
apy in pregnant women with a mechanical heart valve. The purpose of the current
study was to evaluate the clinical results of nadroparin treatment with respect to pre-
gnancy outcome and maternal complications. From 1997 to 2005, 31 pregnancies
were reviewed in 25 women. Nadroparin (7,500 U, twice daily) was used in 23 preg-
nancies between 6 and 12 weeks of gestation and close-to-term only, and coumarin
derivatives were used with aspirin at other times. Eight pregnant women treated
with coumarin derivatives throughout pregnancy were compared to evaluate the
safety and efficacy of nadroparin. No maternal death or bleeding complication occu-
rred in either of the two groups, and frequencies of maternal thromboembolism includ-
ing valve thrombosis (8.7% vs. 12.5%, p>0.05) were similar. However, the frequen-
cies of live born (91.3% vs. 50%, p=0.01) and healthy babies (90.4% vs. 25%, p<
0.01) were significantly higher, and the fetal loss rate was significantly lower (8.7%
vs. 50%, p=0.01) in the nadroparin-treated group. Regarding the efficacy and safety
of antithrombotic treatment in pregnant women with prosthetic heart valves, nadro-
parin treatment during the first trimester is an acceptable regimen and produces
better results than coumarin derivatives.
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consent, concerning the risks and benefits of LMWH. Oth-
ers were anticoagulated with coumarin derivatives (CMD)
with or without aspirin due to unawareness of pregnancy
until the first trimester, or because of refusal or poor compli-
ance on self-injected LMWH. 
In the LMWH-treated group, our anticoagulation protocol
was as follows. When pregnancy was confirmed, coumarins
were stopped and changed to subcutaneous nadroparin (7,500
U, twice daily), from 6 weeks to 12 weeks of gestation. Sub-
sequently, nadroparin was changed to coumarins until the
middle of the third trimester. Aspirin, at 100 mg/day, was
also administrated throughout the pregnancy. At gestation
week 38, women were scheduled for labor induction and
changed to nadroparin to avoid the delivery of an anticoag-
ulated fetus. After establishing labor, we carefully checked
for hemorrhages and other complications, and babies were
examined for congenital anomalies and weight.
In the CMD-treated group, coumarins and aspirin were
continued throughout the pregnancy and the target Interna-
tional Normalized Ratio (INR) was maintained between 2.5
to 3.5. Coumarins were changed to nadroparin before 2 weeks
prior to the expected delivery date to avoid fetal bleeding
complications during delivery.
Pregnancy outcomes, namely, numbers of healthy babies,
fetal anomalies, fetal losses, and maternal complications, in-
cluding thromboembolism or bleeding, were analyzed. To
evaluate the efficacy and safety of LMWH, eight pregnancies,
maintained using coumarins throughout pregnancy, were
compared.
Data were analyzed using SPSS for windows version 10.0
software and compared using the Student’s t-test, at a level
of significance of p<0.05. 
RESULTS
No maternal death or bleeding complication occurred in
either the LMWH-treated group or the CMD-treated group.
Frequencies of maternal thromboembolism were not different
between the two groups (Table 2). A maternal transient ische-
mic attack (TIA) occurred in one case in each group, and both
patients had previously undergone mitral valve replacement.
Prosthetic mitral valve thrombosis occurred in three pregnan-
cies, two in the LMWH group and one in the CMD group
(Table 3). The two of these three patients underwent redo
surgery, and other patient was managed on thrombolytic
therapy. All three patients recovered without complications;
however, their fetal outcomes were unfavorable. 
Numbers of live born and healthy babies were higher in
the LMWH group (Table 4). In both groups, two babies had
low birth weights of 2.1 kg and 2.4 kg, but were otherwise
healthy. In the CMD group, one baby had hydrocephalus.
However, the frequency of fetal loss including therapeutic
abortion and stillbirth were significantly higher in the CMD
group. Two fetal losses occurred in the LMWH group, both
occurred in cases of maternal valve thrombosis. Four fetal
losses occurred in the CMD group, and one of these involved
maternal valve thrombosis. 
DISCUSSION
This study demonstrates that LMWH-based therapy is
LMWH, low molecular weight heparin; CMD, coumarin derivatives; MVR,
mitral valve replacement; AVR, aortic valve replacement; DVR, double
valve replacement.
LMWH (n=23) CMD (n=8)











Table 1. Baseline characteristics of pregnancies (n=31)
LMWH, low molecular weight heparin; CMD, coumarin derivatives; TIA,
transient ischemic attack. *p>0.05.
LMWH (n=23) CMD (n=8)
TIA* 1 (4.3%) 1 (12.5%)
Valve thrombosis* 2 (8.7%) 1 (12.5%)
Mitral 2 1
Aortic 0 0
Table 2. Incidence of materal thromboembolism 
LMWH, low molecular weight heparin; CMD, coumarin derivatives; MVR,
mitral valve replacement.
Group Time Fetus Treatment Age
37 CMD 18 wk stillbirth Redo MVR
28 LMWH 16 wk abortion Thrombolysis
32 LMWH 16 wk abortion Redo MVR
Table 3. Valve thrombosis 
*Low birth weight, ≤2,500 gm.
LMWH, low molecular weight heparin; CMD, coumarin derivatives.
LMWH (n=23) CMD (n=8) p
Live born baby 21 4 0.011
Healthy baby 19 1 0.000
Hydrocephalus 0 1 NS
Low birth weight* 2 2 NS
Fetal loss 2 4 0.011
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superior to coumarin therapy in pregnant women with a pros-
thetic heart valve, and that the use of nadroparin during the
first trimester with 100 mg of aspirin throughout pregnancy
could be a safe and effective protocol for thromboprophylax-
is in these women. 
Recent recommendations, published in 2004 as part of the
7th American College of Chest Physicians (ACCP) consen-
sus on antithrombotic therapy (12), included the following
three regimens: 1) aggressive adjusted-dose LMWH through-
out pregnancy; 2) adjusted-dose UFH, throughout pregnan-
cy; or 3) either LMWH or UFH between 6 and 12 weeks
and close-to-term only and the use of CMD at other times.
In particular, the use of CMD during the first trimester was
not recommended. Our protocol was similar to the third regi-
men, but we also administered aspirin (100 mg daily) thro-
ughout pregnancy to reduce coumarin dosages and the risk
of thromboembolism. The overall frequencies of maternal
thromboembolism, including valve thrombosis, were simi-
lar in both groups, but the frequencies of live and healthy
baby births were higher in the LMWH group. These results
demonstrate that LMWH-based therapy is a good alternative
to coumarins, because it has similar anticoagulation effects
with lower fetal side effects.
Exposure to coumarins during the second part of the first
trimester is associated with fetal loss, primarily due to spon-
taneous abortion or coumarin-induced embryopathy. The
reported frequencies of coumarins-related embryopathy vary
for debatable reasons (14, 15), a recent study suggested that
coumarin risk is dose related and that adverse effects occur
mainly in women taking >5 mg daily. However, this finding
was not confirmed by another study. In our series, the target
INR was maintained with less than 5 mg of coumarins in all
patients in the CMD group; however, a half of these lost their
babies due to abortion or stillbirth. Our results represent only
observational data, and the effect of dose-related embryopa-
thy remains uncertain. Furthermore, the use of coumarins in
pregnant women still poses medicolegal problems.
LMWH does not cross the placental barrier and offers poten-
tial advantages compared with UFH in terms of better safety
profile with less thrombocytopenia, less bleeding, less osteo-
porosis with prolonged treatment, a more predictable and
rapidly reached anticoagulant effect, and the possibility of self-
administration of anticoagulant therapy without laboratory
monitoring. However, treatment failures have been reported,
and the use of LMWH for pregnant women with mechani-
cal heart valves has become controversial due to small num-
bers of patients and a lack of accurate postmarketing data (16).
A recent review of 81 pregnancies in 75 women treated with
LMWH reported an 8.6% rate of valve thrombosis (17), and
found that appropriate dose adjustments could reduce the
frequency of thromboembolism. The 7th ACCP recommen-
dations call for the use of LMWH at levels that achieve peak
anti-factor Xa values of around 1.0 U/mL (12). A recent pro-
spective study with deltaparin reported that dosages based
on body weight were inadequate to maintain a therapeutic
level of LMWH in pregnancy (18). Our data demonstrate
that valve thrombosis occurred in 2 patients treated with nad-
roparin; a prevalence of 8.7%. Unfortunately, we did not moni-
tor anti-Xa levels during nadroparin administration, and
thus, we cannot conclude that valve thrombosis is associated
with an inadequate nadroparin dose. Further studies, with
sufficient statistical power, are required to clarify the clinical
significance of anti-Xa levels.
In conclusion, despite the retrospective design of the pre-
sent study, it might be worth to mention that LMWH appears
a safe and effective substitute for any other anticoagulants in
pregnant women with mechanical heart valves. We have expe-
rienced that pregnancy outcomes are acceptable with LM-
WH, but that its efficacy for preventing valve thrombosis
remains uncertain. Further studies are needed in order to
establish appropriate management protocols for pregnant
women with mechanical heart valves.
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